Erica Hessifer, APRN
Psychiatric/Mental Health · Lake Charles, LANPI 1801262902
Payments from drug & device makers
Across 827 payments — averaging $15.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Neurocrine Biosciences, Inc.$1K
- Alkermes, Inc.$1K
- Johnson & Johnson$888
- plus $5K from 24 others
What the payments were for
- Food & beverage$13,200100%
- Education$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 165 | $2,382 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 68 | $1,295 |
| Otsuka America Pharmaceutical, Inc. | 79 | $1,236 |
| Neurocrine Biosciences, Inc. | 58 | $1,149 |
| Alkermes, Inc. | 69 | $1,013 |
| Johnson & Johnson | 47 | $888 |
| Vanda Pharmaceuticals Inc. | 28 | $609 |
| Corium, LLC | 34 | $573 |
| Takeda Pharmaceuticals U.S.A., Inc. | 42 | $542 |
| Teva Pharmaceuticals USA, Inc. | 40 | $528 |
| Sunovion Pharmaceuticals Inc. | 47 | $521 |
| Axsome Therapeutics, Inc. | 30 | $460 |
| Idorsia Pharmaceuticals US Inc | 24 | $397 |
| Lundbeck LLC | 13 | $254 |
| Supernus Pharmaceuticals, Inc. | 10 | $244 |
| Noven Therapeutics, LLC | 13 | $199 |
| Ironshore Pharmaceuticals Inc. | 17 | $197 |
| Indivior Inc. | 9 | $175 |
| Merck | 7 | $111 |
| Tris Pharma Inc | 6 | $98 |
| E.r. Squibb & Sons, L.L.C. | 4 | $92 |
| Sage Therapeutics, LLC | 3 | $63 |
| Eisai Inc. | 4 | $54 |
| Bausch Health US, LLC | 3 | $43 |
| Bioxcel Therapeutics, Inc. | 2 | $32 |
| Collegium Pharmaceutical, Inc. | 1 | $21 |
| Noven Pharmaceuticals, Inc. | 1 | $18 |
| Alfasigma USA, Inc. | 1 | $14 |
| Neuronetics, Inc. | 1 | $10 |
| OWP Pharmaceuticals, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,222 in reported general payments places this provider in the 95th percentile of 615 psychiatric/mental health providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 20 | $186,418 |
| IngrezzaValbenazine Tosylate | 12 | $102,526 |
| VraylarCariprazine Hcl | 53 | $98,918 |
| Invega SustennaPaliperidone Palmitate | 12 | $47,594 |
| PerserisRisperidone | 12 | $38,051 |
| RexultiBrexpiprazole | 19 | $36,302 |
| Abilify MaintenaAripiprazole | 11 | $32,289 |
| CaplytaLumateperone Tosylate | 15 | $23,790 |
| FanaptIloperidone | 14 | $17,966 |
| BelsomraSuvorexant | 21 | $11,786 |
| Lurasidone Hcl | 31 | $8,056 |
| Divalproex Sodium | 16 | $4,677 |
| Clozapine | 37 | $3,451 |
| Bupropion XlBupropion Hcl | 112 | $2,851 |
| Duloxetine Hcl | 104 | $2,655 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $528 | $186,41820 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,149 | $102,52612 claims |
| AbbVieVraylar | $2,382 | $98,91853 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,236 | $68,59130 claims |
| Johnson & JohnsonInvega Sustenna | $888 | $47,59412 claims |
| Indivior Inc.Perseris | $175 | $38,05112 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,295 | $23,79015 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $609 | $17,96614 claims |
| MerckBelsomra | $111 | $11,78621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 615 psychiatric/mental health providers in Louisiana.
Other psychiatric/mental health in Lake Charles
- Sattaria DilksLake Charles$57K
- Michelle DyerLake Charles$33K
- Candyce BrownLake Charles$13K
- Bethanne CarsonLake Charles$12K
- Morgan UnserLake Charles$9K
- Eric RachalLake Charles$9K
- Lori KayLake Charles$9K
- Valarie ClarkLake Charles$8K
- Julie DyrekLake Charles$8K
- Halie OryLake Charles$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.